Cyclophosphamide cardiotoxicity bone marrow transplantation prospective evaluation new regimens Cyclophosphamide CY cardiotoxicity lethal complication bone marrow transplantation Previous echocardiographic studies ventricular dysfunction due CY occurs patients transplantation cardiotoxicity new protocols CY bone marrow transplantation patients serial ECGs echocardiograms Twenty-six patients once-daily lower-dose protocol mean total mg/kg patients twice-daily higher-dose mean total mg/kg CY regimen higher-dose CY group significant reductions summed ECG voltage left ventricular mass index LVMI first week therapy changes third week CY changes lower-dose group ventricular ejection fraction EF group patients clinical cardiotoxicity pericarditis congestive heart failure patients higher-dose group prior history congestive heart failure baseline EF independent correlate clinical cardiotoxicity dose-dependent cardiotoxicity use CY bone marrow transplantation evident reversible decreases ECG voltage increases left ventricular mass myocardial edema hemorrhage systolic dysfunction common new regimens studies high-dose once-daily CY 